OPOK Health (OPK) is a publicly traded pharmaceutical and medical testing company. The company’s stock trades under the symbol “OPK.” OPKO is a good pick for investors because it has a long history of creating quality products that benefit patients. As a pharmaceutical company, OPKO produces diagnostic tests for a variety of diseases.
OPKO has been on an acquisition spree recently. In 2013, it paid $480 million for the Israeli company Prolor Biotech and another $100 million for the Canadian biotechnology Cytochroma. In 2015, it paid $1.5 billion for BioReference Labs. It also spent $135 million on Irish biotech EirGen. In 2016, OPKO bought Transition Therapeutics for $60 million. It also purchased Curna Health in 2011 for $10 million. OPOK Health invests in a large number of healthcare companies, including microcaps, but it also has a focus on smaller companies that may not have yet developed commercial products.
OPKO’s stock is being targeted by short sellers. The stock has fallen from a high of $19 in 2015 to $0.50 in recent months. However, the stock is not in danger of becoming a micro-cap, as its current market cap is over $1 billion. Despite the short sellers’ efforts, the company’s stock still maintains a healthy valuation of $1 billion. However, it has received some bad press from investors.
OPOK Health is a pharmaceutical and diagnostics company. However, it has been the subject of controversy in recent years. Short sellers have been selling 24% of the company’s float. The short sellers hope to profit by repurchasing the stock at a later date. Essentially, they are betting that the stock will fall in the future and that OPKO’s stock will be less expensive than their original purchase price.
A few years ago, OPOK Health was valued at $7 billion. Its shares fell sharply when the CEO’s vision failed to materialize. Even with the recent downturn, OPKO Health still has tremendous potential and is managed by a proven CEO who has a track record of finding unrealized value.
ALSO READ: car accident attorney los angeles cz.law
 Stock Review. Read More!){kind=link}